Claritas Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
There is insufficient data on Claritas Pharmaceuticals's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | n/a |
Return on equity | 55.0% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Claritas Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 21 | 0 | 2 | 2 | -2 |
30 Jun 21 | 0 | 2 | 2 | -2 |
31 Mar 21 | 0 | -12 | 2 | -2 |
31 Dec 20 | 0 | 4 | 2 | -2 |
30 Sep 20 | 0 | -7 | 2 | 0 |
30 Jun 20 | 0 | -8 | 2 | 1 |
31 Mar 20 | 0 | -1 | 3 | 3 |
31 Dec 19 | 0 | -21 | 4 | 6 |
30 Sep 19 | 0 | -12 | 4 | 8 |
30 Jun 19 | 0 | -9 | 4 | 9 |
31 Mar 19 | 0 | 2 | 3 | 9 |
31 Dec 18 | 0 | 7 | 3 | 8 |
30 Sep 18 | 0 | -21 | 3 | 6 |
30 Jun 18 | 0 | -24 | 3 | 4 |
31 Mar 18 | 0 | -32 | 3 | 3 |
31 Dec 17 | 0 | -32 | 3 | 2 |
30 Sep 17 | 0 | -14 | 5 | 2 |
30 Jun 17 | 0 | -13 | 5 | 2 |
31 Mar 17 | 0 | -13 | 4 | 2 |
31 Dec 16 | 0 | -12 | 3 | 2 |
30 Sep 16 | 0 | -3 | 2 | 1 |
Quality Earnings: CLAS has a high level of non-cash earnings.
Growing Profit Margin: CLAS became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLAS has become profitable over the past 5 years.
Accelerating Growth: CLAS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CLAS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: CLAS's Return on Equity (55%) is considered outstanding.